ARCH-backed SciNeuro kicks off search for CNS autoantibodies with new deal; Merck + Gilead announce PhII trial for HIV combo
From the very beginning at SciNeuro, CEO Min Li has envisioned a mix of licensing deals and scientific efforts to replicate the breakout success …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
